130 related articles for article (PubMed ID: 34119429)
1. An Evaluation of Clinicopathological Correlation and Outcome of Human Epidermal Growth Factor Receptor 2 Subgroups Reclassified According to the Latest ASCO/CAP Guideline.
Wang C; Tsang JY; Poon IK; Shao Y; Li JJ; Shea KH; Hlaing T; Wong SI; Tse GM
Clin Breast Cancer; 2022 Jan; 22(1):e114-e122. PubMed ID: 34119429
[TBL] [Abstract][Full Text] [Related]
2. The updated 2018 American Society of Clinical Oncology/College of American Pathologists guideline on human epidermal growth factor receptor 2 interpretation in breast cancer: comparison with previous guidelines and clinical significance of the proposed in situ hybridization groups.
Woo JW; Lee K; Chung YR; Jang MH; Ahn S; Park SY
Hum Pathol; 2020 Apr; 98():10-21. PubMed ID: 32027910
[TBL] [Abstract][Full Text] [Related]
3. Next-generation assessment of human epidermal growth factor receptor 2 gene (ERBB2) amplification status in invasive breast carcinoma: a focus on Group 4 by use of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 testing guideline.
Hoda RS; Bowman AS; Zehir A; Razavi P; Brogi E; Ladanyi M; Arcila ME; Wen HY; Ross DS
Histopathology; 2021 Mar; 78(4):498-507. PubMed ID: 32841416
[TBL] [Abstract][Full Text] [Related]
4. Updated 2013 College of American Pathologists/American Society of Clinical Oncology (CAP/ASCO) guideline recommendations for human epidermal growth factor receptor 2 (HER2) fluorescent in situ hybridization (FISH) testing increase HER2 positive and HER2 equivocal breast cancer cases; retrospective study of HER2 FISH results of 836 invasive breast cancers.
Singh K; Tantravahi U; Lomme MM; Pasquariello T; Steinhoff M; Sung CJ
Breast Cancer Res Treat; 2016 Jun; 157(3):405-11. PubMed ID: 27180259
[TBL] [Abstract][Full Text] [Related]
5. Impact of the 2013 American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 (HER2) testing of invasive breast carcinoma: a focus on tumours assessed as 'equivocal' for HER2 gene amplification by fluorescence in-situ hybridization.
Bethune GC; Veldhuijzen van Zanten D; MacIntosh RF; Rayson D; Younis T; Thompson K; Barnes PJ
Histopathology; 2015 Dec; 67(6):880-7. PubMed ID: 25913507
[TBL] [Abstract][Full Text] [Related]
6. The differences of clinicopathologic characteristics among subgroups of reclassified HER2 fluorescence in situ hybridization (FISH) according to the ASCO/CAP 2018 breast cancer HER2 testing guidelines.
Yang L; Chen M; Pu T; Wu S; Wei B; Yang J; Bu H; Zhang Z
J Clin Pathol; 2020 May; 73(5):283-290. PubMed ID: 31732618
[TBL] [Abstract][Full Text] [Related]
7. Breast cancers with a HER2/CEP17 ratio of 2.0 or greater and an average HER2 copy number of less than 4.0 per cell: frequency, immunohistochemical correlation, and clinicopathological features.
Zare SY; Lin L; Alghamdi AG; Daehne S; Roma AA; Hasteh F; Dell'Aquila M; Fadare O
Hum Pathol; 2019 Jan; 83():7-13. PubMed ID: 30121371
[TBL] [Abstract][Full Text] [Related]
8. Impact of an alternative chromosome 17 probe and the 2013 American Society of Clinical Oncology and College of American Pathologists guidelines on fluorescence in situ hybridization for the determination of HER2 gene amplification in breast cancer.
Donaldson AR; Shetty S; Wang Z; Rivera CL; Portier BP; Budd GT; Downs-Kelly E; Lanigan CP; Calhoun BC
Cancer; 2017 Jun; 123(12):2230-2239. PubMed ID: 28192599
[TBL] [Abstract][Full Text] [Related]
9. Impact of the 2018 American Society of Clinical Oncology/College of American Pathologists HER2 Guideline Updates on HER2 Assessment in Breast Cancer With Equivocal HER2 Immunohistochemistry Results With Focus on Cases With
Hoda RS; Brogi E; Xu J; Ventura K; Ross DS; Dang C; Robson M; Norton L; Morrow M; Wen HY
Arch Pathol Lab Med; 2020 May; 144(5):597-601. PubMed ID: 31647316
[TBL] [Abstract][Full Text] [Related]
10. Impact of American Society of Clinical Oncology/College of American Pathologists guideline recommendations on HER2 interpretation in breast cancer.
Shah SS; Ketterling RP; Goetz MP; Ingle JN; Reynolds CA; Perez EA; Chen B
Hum Pathol; 2010 Jan; 41(1):103-6. PubMed ID: 19762065
[TBL] [Abstract][Full Text] [Related]
11. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update.
Wolff AC; Hammond MEH; Allison KH; Harvey BE; Mangu PB; Bartlett JMS; Bilous M; Ellis IO; Fitzgibbons P; Hanna W; Jenkins RB; Press MF; Spears PA; Vance GH; Viale G; McShane LM; Dowsett M
Arch Pathol Lab Med; 2018 Nov; 142(11):1364-1382. PubMed ID: 29846104
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathologic features of breast cancer reclassified as HER2-amplified by fluorescence in situ hybridization with alternative chromosome 17 probes.
Blanton KC; Deal AM; Kaiser-Rogers KA; Anders CK; O'Connor SM; Hertel JD; Calhoun BC
Ann Diagn Pathol; 2020 Oct; 48():151576. PubMed ID: 32805517
[TBL] [Abstract][Full Text] [Related]
13. Impact of the updated 2018 American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines on Human Epidermal Growth Factor Receptor 2 (HER2) gene testing in invasive breast cancers: A single center study.
Lim TH; Lim AST; Tien SL; Tan PH
Ann Diagn Pathol; 2022 Jun; 58():151935. PubMed ID: 35313158
[TBL] [Abstract][Full Text] [Related]
14. Clinical and Pathologic Features Associated With Invasive Breast Carcinoma With 2018 American Society of Clinical Oncology/College of American Pathologists In Situ Hybridization Group 2 Results (Human Epidermal Growth Factor Receptor 2 [HER2]/Chromosome 17 Centromere [CEP17] Ratio ≥2.0 and Average HER2 Copy Number <4.0).
Hoda RS; Zarei S; McIntire PJ; Sprague C; Mekhail Y; Carlson DL; Komforti MK; Downs-Kelly EP
Arch Pathol Lab Med; 2022 Jun; 146(6):701-709. PubMed ID: 34559875
[TBL] [Abstract][Full Text] [Related]
15. Rate of reclassification of HER2-equivocal breast cancer cases to HER2-negative per the 2018 ASCO/CAP guidelines and response of HER2-equivocal cases to anti-HER2 therapy.
Crespo J; Sun H; Wu J; Ding QQ; Tang G; Robinson MK; Chen H; Sahin AA; Lim B
PLoS One; 2020; 15(11):e0241775. PubMed ID: 33180796
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Updated 2018 American Society of Clinical Oncology/College of American Pathologists Guideline for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer.
Li A; Bai Q; Kong H; Zhou S; Lv H; Zhong S; Li M; Bi R; Zhou X; Yang W
Arch Pathol Lab Med; 2020 Sep; 144(9):1097-1107. PubMed ID: 32142367
[TBL] [Abstract][Full Text] [Related]
17. Impact of the updated 2018 ASCO/CAP guidelines on HER2 FISH testing in invasive breast cancer: a retrospective study of HER2 fish results of 2233 cases.
Liu ZH; Wang K; Lin DY; Xu J; Chen J; Long XY; Ge Y; Luo XL; Zhang KP; Liu YH; Xu FP
Breast Cancer Res Treat; 2019 May; 175(1):51-57. PubMed ID: 30712197
[TBL] [Abstract][Full Text] [Related]
18. Implementation of the 2018 American Society of Clinical Oncology/College of American Pathologists Guidelines on HER2/neu Assessment by FISH in breast cancers: predicted impact in a single institutional cohort.
Zare S; Rong J; Daehne S; Roma A; Hasteh F; Dell'Aquila M; Fadare O
Mod Pathol; 2019 Nov; 32(11):1566-1573. PubMed ID: 31190000
[TBL] [Abstract][Full Text] [Related]
19. Implications of the Updated 2013 American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations on Human Epidermal Growth Factor Receptor 2 Gene Testing Using Immunohistochemistry and Fluorescence In Situ Hybridization for Breast Cancer.
Lim TH; Lim AS; Thike AA; Tien SL; Tan PH
Arch Pathol Lab Med; 2016 Feb; 140(2):140-7. PubMed ID: 26910218
[TBL] [Abstract][Full Text] [Related]
20. Impact of Modified 2013 ASCO/CAP Guidelines on HER2 Testing in Breast Cancer. One Year Experience.
Varga Z; Noske A
PLoS One; 2015; 10(10):e0140652. PubMed ID: 26473483
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
